Janssen Japan President Chris Hourigan named new Company Group Chairman for Janssen Asia Pacific

Janssen Japan President Chris Hourigan named new Company Group Chairman for Janssen Asia Pacific

SINGAPORE, October 14, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that Chris Hourigan has been promoted to lead their operations across eight markets in Asia Pacific.

After five years as President of Janssen Japan, Mr. Hourigan will now report to the Worldwide Chairman for Pharmaceuticals in overseeing Janssen operations in Asia Pacific.

Worldwide Chairman of Pharmaceuticals Jennifer Taubert congratulated Mr. Hourigan on his appointment, stating that he had led Janssen Japan with “determination and drive to deliver for patients.”

“Chris has done an outstanding job leading our pharmaceuticals business in Japan with a focus on market competitiveness, access to innovative medicines, and attracting and developing top talent,” she said.

Year to date, Janssen Japan is the second-fastest growing pharmaceutical company in Japan, the number one for growth over the past five years amongst the top 15 companiesi, and the second-largest Janssen business globally.

Mr. Hourigan is a highly respected member of the Japanese pharmaceutical industry, well recognised for his work to increase access to innovative medicines. As Chair of PhRMA Japan and previous board member of EFPIA Japan, Mr. Hourigan engaged with the Japanese Government on the value of pharmaceutical innovation and led an industry taskforce on new government HTA policy.

“I am grateful for the opportunity to have led Janssen Japan since 2016 and incredibly proud of the journey our determined and capable team has taken together,” Mr. Hourigan said.

“We worked to find pathways for improvement across all areas of the business, which has left Janssen Japan in a strong position to deliver for the growing number of patients and healthcare professionals who depend on our medicines.”

Mr. Hourigan has more than 25 years of experience in the pharmaceutical industry. Since joining Janssen Australia in 2005, he has worked across five countries in positions of increasing responsibility. Before moving to Japan, this included successful roles as country

Page 2 of 2

manager for Australia & New Zealand, Vietnam, and New Zealand. He also worked in the United States as Global Marketing Lead for the Janssen Psychiatry business unit.

Mr. Hourigan succeeds Ai Hua Ong as Company Group Chairman, Pharmaceuticals, Asia Pacific. Ms. Ong has been appointed Head of Government Affairs & Policy for Johnson & Johnson in Asia Pacific where she will be responsible for the engagement of key government stakeholders to help shape health policy, medicines access, environmental regulation, and regulatory compliance.

About the Janssen Pharmaceutical Companies of Johnson & Johnson

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Learn more at https://www.janssen.com/apac/. Follow us at www.twitter.com/JanssenAP.

i Pharma Market Insights 2020 Spring Edition, IQVIA Solution Japan